following a full submission assessed under the ultra-orphan medicine process:
conestat alfa (Ruconest®) is accepted for use within NHSScotland.
Indication under review: For treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency.
Conestat alfa was associated with a significantly shorter time to relief from symptoms of HAE attack compared with placebo during controlled phase III studies.
This SMC advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of conestat alfa. This advice is contingent upon the continuing availability of the PAS in NHS Scotland or a list price that is equivalent or lower.
This advice takes account of views from a Patient and Clinician Engagement (PACE) meeting.
Download detailed advice154KB (PDF)
- Medicine name:
- conestat alfa (Ruconest)
- SMC ID:
- Treatment of acute angioedema attacks in adults and adolescents with hereditary angioedema (HAE) due to C1 esterase inhibitor deficiency
- Pharmaceutical company
- Pharming Group NV
- BNF chapter
- Respiratory system
- Submission type
- Date advice published:
- 13 August 2018